Shinya Sato1, Hiroaki Itamochi. 1. Department of Obstetrics and Gynecology, Tottori University School of Medicine, Yonago, Tottori, Japan.
Abstract
PURPOSE OF REVIEW: Vascular endothelial growth factor (VEGF), one of the major pathways involved in tumor angiogenesis, is often overexpressed in epithelial ovarian cancer (EOC), and therefore an attractive target for therapy. This review aims to evaluate the rationale for targeting angiogenic pathways by the usage of the anti-VEGF agent bevacizumab in EOC. RECENT FINDINGS: Bevacizumab monotherapy has been shown to be effective in the treatment of EOC with response rate of 16-21% in phase II trials. In phase III trials, patients with advanced EOC who received combination chemotherapy (paclitaxel + carboplatin) plus bevacizumab with maintenance bevacizumab had significantly longer progression-free survival than those who received chemotherapy alone, but did not prolong overall survival. The most common grade 3/4 adverse events of bevacizumab monotherapy include hypertension and proteinuria, while heavily pretreated patients were at increased risk of bowel perforation. The addition of bevacizumab to the standard chemotherapy in patients with advanced EOC may not be cost-effective. SUMMARY: Bevacizumab has significant activity and is the most promising drug in EOC. However, understanding of its unique adverse events and identification of predictive biomarkers of bevacizumab response are necessary in order to select patients most likely to benefit from this therapy.
PURPOSE OF REVIEW: Vascular endothelial growth factor (VEGF), one of the major pathways involved in tumor angiogenesis, is often overexpressed in epithelial ovarian cancer (EOC), and therefore an attractive target for therapy. This review aims to evaluate the rationale for targeting angiogenic pathways by the usage of the anti-VEGF agent bevacizumab in EOC. RECENT FINDINGS:Bevacizumab monotherapy has been shown to be effective in the treatment of EOC with response rate of 16-21% in phase II trials. In phase III trials, patients with advanced EOC who received combination chemotherapy (paclitaxel + carboplatin) plus bevacizumab with maintenance bevacizumab had significantly longer progression-free survival than those who received chemotherapy alone, but did not prolong overall survival. The most common grade 3/4 adverse events of bevacizumab monotherapy include hypertension and proteinuria, while heavily pretreated patients were at increased risk of bowel perforation. The addition of bevacizumab to the standard chemotherapy in patients with advanced EOC may not be cost-effective. SUMMARY:Bevacizumab has significant activity and is the most promising drug in EOC. However, understanding of its unique adverse events and identification of predictive biomarkers of bevacizumab response are necessary in order to select patients most likely to benefit from this therapy.
Authors: Zhen Lu; Maria T Baquero; Hailing Yang; Maojie Yang; Albert S Reger; Choel Kim; Douglas A Levine; Charlotte H Clarke; Warren S-L Liao; Robert C Bast Journal: Autophagy Date: 2014-06 Impact factor: 16.016
Authors: Vsevolod I Kiselev; Levon A Ashrafyan; Ekaterina L Muyzhnek; Evgeniya V Gerfanova; Irina B Antonova; Olga I Aleshikova; Fazlul H Sarkar Journal: BMC Cancer Date: 2018-09-20 Impact factor: 4.430
Authors: Floor C J van de Watering; Mark Rijpkema; Lars Perk; Ulrich Brinkmann; Wim J G Oyen; Otto C Boerman Journal: Biomed Res Int Date: 2014-05-28 Impact factor: 3.411